{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:38:40Z","timestamp":1792669120821,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T00:00:00Z","timestamp":1424217600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00417-015-2954-x","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T04:29:49Z","timestamp":1424147389000},"page":"1061-1069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model"],"prefix":"10.1007","volume":"253","author":[{"given":"David","family":"Kuerten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Johnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Harmening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Souteyrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Thumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,18]]},"reference":[{"key":"2954_CR1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s004170100313","volume":"239","author":"C Cursiefen","year":"2001","unstructured":"Cursiefen C, Wenkel H, Martus P et al (2001) Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 239:514\u2013521","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2954_CR2","first-page":"98","volume":"25","author":"YWG Qazi","year":"2010","unstructured":"Qazi YWG, Monson B, Jack Stringham J, Ambati BK (2010) Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull 25:98\u2013210","journal-title":"Brain Res Bull"},{"issue":"5","key":"2954_CR3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1083\/jcb.141.5.1277","volume":"141","author":"S Chakravarti","year":"1998","unstructured":"Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H (1998) Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 141(5):1277\u20131286","journal-title":"J Cell Biol"},{"issue":"4","key":"2954_CR4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","volume":"12","author":"JH Chang","year":"2001","unstructured":"Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12(4):242\u2013249","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"2954_CR5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archopht.121.8.1087","volume":"121","author":"MO Price","year":"2003","unstructured":"Price MO, Thompson RW Jr, Price FW Jr (2003) Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol 121(8):1087\u20131092. doi: 10.1001\/archopht.121.8.1087","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"2954_CR6","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","volume":"45","author":"C Cursiefen","year":"2004","unstructured":"Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse F, Wiegand S, Dana M, Streilein J (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45(8):2666\u20132673","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"2954_CR7","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1167\/iovs.08-1997","volume":"50","author":"WL Chen","year":"2009","unstructured":"Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR (2009) Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50(4):1659\u20131665. doi: 10.1167\/iovs. 08-1997","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"2954_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ICU.0b013e32831d7f3a","volume":"20","author":"KE Bollinger","year":"2009","unstructured":"Bollinger KE, Smith SD (2009) Prevalence and management of elevated intraocular pressure after placement of an intravitreal sustained-release steroid implant. Curr Opin Ophthalmol 20(2):99\u2013103","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"2954_CR9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000224783","volume":"42","author":"MN Hashemian","year":"2009","unstructured":"Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA (2009) Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 42(2):90\u201395. doi: 10.1159\/000224783","journal-title":"Ophthalmic Res"},{"issue":"7","key":"2954_CR10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ophtha.2005.03.013","volume":"112","author":"GJ Jaffe","year":"2005","unstructured":"Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P (2005) Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112(7):1192\u20131198. doi: 10.1016\/j.ophtha.2005.03.013","journal-title":"Ophthalmology"},{"issue":"2","key":"2954_CR11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0039-6257(86)90077-9","volume":"31","author":"RC Urban Jr","year":"1986","unstructured":"Urban RC Jr, Cotlier E (1986) Corticosteroid-induced cataracts. Surv Ophthalmol 31(2):102\u2013110. doi: 10.1016\/0039-6257(86)90077-9","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"2954_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1076\/ceyr.23.1.1.5422","volume":"23","author":"V Mastyugin","year":"2001","unstructured":"Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML (2001) Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 23(1):1\u201310","journal-title":"Curr Eye Res"},{"issue":"4","key":"2954_CR13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","volume":"70","author":"A Kvanta","year":"2000","unstructured":"Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B (2000) Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70(4):419\u2013428. doi: 10.1006\/exer.1999.0790","journal-title":"Exp Eye Res"},{"issue":"1","key":"2954_CR14","first-page":"18","volume":"39","author":"S Amano","year":"1998","unstructured":"Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39(1):18\u201322","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2954_CR15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","volume":"27","author":"CXBI Qian","year":"2008","unstructured":"Qian CXBI, Levinger E, Rootman D (2008) Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:1090\u20131092","journal-title":"Cornea"},{"issue":"4","key":"2954_CR16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","volume":"150","author":"JJ Perez-Santonja","year":"2010","unstructured":"Perez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M, Javaloy J, Alio JL (2010) Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol 150(4):519\u2013528. doi: 10.1016\/j.ajo.2010.04.024 , e511","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2954_CR17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","volume":"145","author":"M Papathanassiou","year":"2008","unstructured":"Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145(3):424\u2013431. doi: 10.1016\/j.ajo.2007.11.003","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2954_CR18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3341\/kjo.2010.24.4.230","volume":"24","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, Jeong HO, Chung SK (2010) The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol 24(4):230\u2013236. doi: 10.3341\/kjo.2010.24.4.230","journal-title":"Korean J Ophthalmol"},{"issue":"6","key":"2954_CR19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48(6):2545\u20132552. doi: 10.1167\/iovs. 06-0570","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"2954_CR20","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1073\/pnas.0611492104","volume":"104","author":"HP Gerber","year":"2007","unstructured":"Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 104(9):3478\u20133483. doi: 10.1073\/pnas.0611492104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"2954_CR21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jneuroim.2004.11.013","volume":"160","author":"M Flier van der","year":"2005","unstructured":"van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, Kimpen JL, Hoepelman AI, Geelen SP (2005) Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. J Neuroimmunol 160(1\u20132):170\u2013177. doi: 10.1016\/j.jneuroim.2004.11.013","journal-title":"J Neuroimmunol"},{"issue":"4","key":"2954_CR22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","volume":"127","author":"MH Dastjerdi","year":"2009","unstructured":"Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, Pavan-Langston D, Dana R (2009) Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 127(4):381\u2013389. doi: 10.1001\/archophthalmol.2009.18","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"2954_CR23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"F Bock","year":"2008","unstructured":"Bock F, Konig Y, Kruse F, Baier M, Cursiefen C (2008) Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246(2):281\u2013284. doi: 10.1007\/s00417-007-0684-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2954_CR24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","volume":"97","author":"C Petsoglou","year":"2013","unstructured":"Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ (2013) Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 97(1):28\u201332. doi: 10.1136\/bjophthalmol-2012-302137","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"2954_CR25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jfo.2010.07.007","volume":"33","author":"J Gueudry","year":"2010","unstructured":"Gueudry J, Richez F, Tougeron-Brousseau B, Genevois O, Muraine M (2010) Subconjunctival bevacizumab for corneal neovascularization. J Fr Ophtalmol 33(9):630\u2013636. doi: 10.1016\/j.jfo.2010.07.007","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"2954_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","volume":"35","author":"MR Fallah","year":"2010","unstructured":"Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M (2010) Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 35(1):17\u201322. doi: 10.3109\/02713680903395273","journal-title":"Curr Eye Res"},{"issue":"1","key":"2954_CR27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ICO.0b013e3181e458c5","volume":"30","author":"HS Chu","year":"2011","unstructured":"Chu HS, Hu FR, Yang CM, Yeh PT, Chen YM, Hou YC, Chen WL (2011) Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition. Cornea 30(1):60\u201366. doi: 10.1097\/ICO.0b013e3181e458c5","journal-title":"Cornea"},{"issue":"4","key":"2954_CR28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/09273948.2010.490630","volume":"18","author":"SA Bayar","year":"2010","unstructured":"Bayar SA, Altinors DD, Kucukerdonmez C, Akova YA (2010) Severe corneal changes following intravitreal injection of bevacizumab. Ocul Immunol Inflamm 18(4):268\u2013274. doi: 10.3109\/09273948.2010.490630","journal-title":"Ocul Immunol Inflamm"},{"key":"2954_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/15428877-20100215-07","volume":"9","author":"A Galor","year":"2010","unstructured":"Galor A, Yoo SH (2010) Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging 9:1-3. doi: 10.3928\/15428877-20100215-07","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"10","key":"2954_CR30","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1167\/iovs.08-2805","volume":"50","author":"TI Kim","year":"2009","unstructured":"Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK (2009) Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 50(10):4653\u20134659. doi: 10.1167\/iovs. 08-2805","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"2954_CR31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.expneurol.2004.01.022","volume":"187","author":"JM Rosenstein","year":"2004","unstructured":"Rosenstein JM, Krum JM (2004) New roles for VEGF in nervous tissue\u2013beyond blood vessels. Exp Neurol 187(2):246\u2013253. doi: 10.1016\/j.expneurol.2004.01.022","journal-title":"Exp Neurol"},{"issue":"9","key":"2954_CR32","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1167\/iovs.07-1418","volume":"49","author":"CQ Yu","year":"2008","unstructured":"Yu CQ, Zhang M, Matis KI, Kim C, Rosenblatt MI (2008) Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 49(9):3870\u20133878. doi: 10.1167\/iovs. 07-1418","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"2954_CR33","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","volume":"50","author":"F Bock","year":"2009","unstructured":"Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlotzer-Schrehardt U, Cursiefen C (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50(5):2095\u20132102. doi: 10.1167\/iovs. 07-1129","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"16","key":"2954_CR34","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232\u20131239. doi: 10.1093\/jnci\/djm086","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"2954_CR35","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"SA Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180\u20135186. doi: 10.1200\/JCO.2007.12.0782","journal-title":"J Clin Oncol"},{"issue":"5425","key":"2954_CR36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.285.5425.245","volume":"285","author":"DW Dawson","year":"1999","unstructured":"Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425):245\u2013248","journal-title":"Science"},{"issue":"1","key":"2954_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/bjo.2011.204701","volume":"96","author":"C Cursiefen","year":"2012","unstructured":"Cursiefen C, Colin J, Dana R, Diaz-Llopis M, Faraj LA, Garcia-Delpech S, Geerling G, Price FW, Remeijer L, Rouse BT, Seitz B, Udaondo P, Meller D, Dua H (2012) Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol 96(1):3\u20139. doi: 10.1136\/bjo.2011.204701","journal-title":"Br J Ophthalmol"},{"issue":"7114","key":"2954_CR38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","volume":"443","author":"BK Ambati","year":"2006","unstructured":"Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443(7114):993\u2013997. doi: 10.1038\/nature05249","journal-title":"Nature"},{"issue":"5","key":"2954_CR39","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-08-2113","volume":"15","author":"Y Mirochnik","year":"2009","unstructured":"Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C, Volpert OV (2009) Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res 15(5):1655\u20131663. doi: 10.1158\/1078-0432.CCR-08-2113","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2954_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.1.02008","volume":"37","author":"SX Zhang","year":"2006","unstructured":"Zhang SX, Wang JJ, Gao G, Parke K, Ma JX (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37(1):1\u201312. doi: 10.1677\/jme.1.02008","journal-title":"J Mol Endocrinol"},{"issue":"6","key":"2954_CR41","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1074\/jbc.M507401200","volume":"281","author":"J Cai","year":"2006","unstructured":"Cai J, Jiang WG, Grant MB, Boulton M (2006) Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281(6):3604\u20133613. doi: 10.1074\/jbc.M507401200","journal-title":"J Biol Chem"},{"key":"2954_CR42","first-page":"1168","volume":"43","author":"N Ogata","year":"2002","unstructured":"Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M (2002) Expression of pigment epithelium-derived factor in normal adult Rat Eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43:1168\u20131175","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2954_CR43","first-page":"154","volume":"7","author":"C Petros","year":"2001","unstructured":"Petros C, Karakousis PC, John SK et al (2001) Localization of epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 7:154\u2013163","journal-title":"Mol Vis"},{"issue":"5","key":"2954_CR44","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.exer.2009.06.021","volume":"89","author":"CN Kuo","year":"2009","unstructured":"Kuo CN, Yang LC, Yang CT, Lai CH, Chen MF, Chen CY, Chen CH, Wu PC, Kou HK, Chen YJ, Hung CH, Tsai CB (2009) Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis. Exp Eye Res 89(5):678\u2013685. doi: 10.1016\/j.exer.2009.06.021","journal-title":"Exp Eye Res"},{"issue":"6","key":"2954_CR45","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1167\/iovs.03-0882","volume":"45","author":"C Shao","year":"2004","unstructured":"Shao C, Sima J, Zhang SX, Jin J, Reinach P, Wang Z, Ma JX (2004) Suppression of corneal neovascularization by PEDF release from human amniotic membranes. Invest Ophthalmol Vis Sci 45(6):1758\u20131762","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2954_CR46","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/ICO.0b013e3181cc7987","volume":"29","author":"J Jin","year":"2010","unstructured":"Jin J, Ma JX, Guan M, Yao K (2010) Inhibition of chemical cautery-induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops. Cornea 29:1055\u20131061","journal-title":"Cornea"},{"issue":"4","key":"2954_CR47","doi-asserted-by":"crossref","first-page":"8291","DOI":"10.3390\/ijms14048291","volume":"14","author":"CN Kuo","year":"2013","unstructured":"Kuo CN, Chen CY, Chen SN, Yang LC, Lai LJ, Lai CH, Chen MF, Hung CH, Chen CH (2013) Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a Rat corneal experimental angiogenesis model. Int J Mol Sci 14(4):8291\u20138305. doi: 10.3390\/ijms14048291","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2954_CR48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/jpet.112.192575","volume":"342","author":"YJ Bai","year":"2012","unstructured":"Bai YJ, Huang LZ, Xu XL, Du W, Zhou AY, Yu WZ, Li XX (2012) Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther 342(1):131\u2013139. doi: 10.1124\/jpet.112.192575","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2954_CR49","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1167\/iovs.12-9951","volume":"53","author":"S Johnen","year":"2012","unstructured":"Johnen S, Izsvak Z, Stocker M, Harmening N, Salz AK, Walter P, Thumann G (2012) Sleeping beauty transposon-mediated transfection of retinal and iris pigment epithelial cells. Invest Ophthalmol Vis Sci 53(8):4787\u20134796. doi: 10.1167\/iovs. 12-9951","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2954_CR50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/gt.2009.124","volume":"17","author":"G Thumann","year":"2010","unstructured":"Thumann G, St\u00f6cker M, Maltusch C, Salz AK, Barth S, Walter P, Johnen S (2010) High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Ther 17:181\u2013189","journal-title":"Gene Ther"},{"issue":"2","key":"2954_CR51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","volume":"27","author":"I Bahar","year":"2008","unstructured":"Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27(2):142\u2013147. doi: 10.1097\/ICO.0b013e318159019f","journal-title":"Cornea"},{"issue":"3","key":"2954_CR52","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2702.1999.00250.x","volume":"8","author":"NA Olleveant","year":"1999","unstructured":"Olleveant NA, Humphris G, Roe B (1999) How big is a drop? A volumetric assay of essential oils. J Clin Nurs 8(3):299\u2013304","journal-title":"J Clin Nurs"},{"issue":"3","key":"2954_CR53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4","volume":"261","author":"RJ Tomanek","year":"2000","unstructured":"Tomanek RJ, Schatteman GC (2000) Angiogenesis: new insights and therapeutic potential. Anat Rec 261(3):126\u2013135. doi: 10.1002\/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4","journal-title":"Anat Rec"},{"issue":"8","key":"2954_CR54","first-page":"1619","volume":"38","author":"S Grisanti","year":"1997","unstructured":"Grisanti S, Ishioka M, Kosiewicz M, Jiang LQ (1997) Immunity and immune privilege elicited by cultured retinal pigment epithelial cell transplants. Invest Ophthalmol Vis Sci 38(8):1619\u20131626","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-015-2954-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-015-2954-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-015-2954-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T23:21:48Z","timestamp":1691277708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-015-2954-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,18]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["2954"],"URL":"https:\/\/doi.org\/10.1007\/s00417-015-2954-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,18]]}}}